Background
==========

Intraoperative and postoperative bleeding remains a common major complication of surgery.[@b1-ceor-7-409]--[@b5-ceor-7-409] An aging population with growing comorbidities and high anticoagulant use are important factors that contribute to high surgical bleeding risks.[@b6-ceor-7-409]--[@b8-ceor-7-409] Surgical bleeding can range from mild or moderate in intensity to severe or traumatic. There are a number of conventional surgical methods (eg, suture, ligature, compression, and cautery) and topical absorbable hemostats (TAHs) available to achieve hemostasis in mild to moderate bleeding scenarios.[@b9-ceor-7-409]--[@b13-ceor-7-409] Hemostatic agents in particular have become a growing treatment option over the past couple of decades, and have been associated with improved surgical and clinical outcomes.[@b14-ceor-7-409]

Mild or moderate surgical bleeding may be straightforward to manage; however, bleeding may also be problematic or difficult to control, depending on several factors including bleeding severity, visibility and access to the bleeding source, anatomic location of the bleeding, patient coagulation status, and surgical skill.[@b12-ceor-7-409] These types of bleeding scenarios are often referred to in the literature using several common bleeding terms including severe,[@b1-ceor-7-409] major,[@b5-ceor-7-409] or excessive.[@b15-ceor-7-409] For example, diffuse bleeding from broad surface areas in patients who are coagulopathic may be particularly difficult to manage which may lead to additional procedures such as blood transfusion.[@b9-ceor-7-409],[@b12-ceor-7-409] Traumatic bleeding may be placed at the top of this spectrum where patients have severe bleeding from injured tissues and often traditional methods of hemostasis are ineffective, necessitating multiple units of transfused blood.[@b16-ceor-7-409],[@b17-ceor-7-409]

In more problematic and difficult bleeding, there is often no single solution that can allow surgeons to rapidly stop bleeding.[@b18-ceor-7-409]--[@b20-ceor-7-409] As a result, these situations often involve combinational use of hemostatic products in addition to conventional methods, which may be cumbersome, time-consuming, and costly.[@b12-ceor-7-409],[@b21-ceor-7-409] Furthermore, several studies describe the substantial clinical and economic burden with such bleeding.[@b15-ceor-7-409],[@b16-ceor-7-409],[@b22-ceor-7-409]--[@b24-ceor-7-409] Bleeding can lengthen, interrupt, or complicate the surgery as well as increase likelihood of transfusion, reoperation, and associated complications.[@b22-ceor-7-409],[@b25-ceor-7-409]--[@b28-ceor-7-409] Furthermore, it has been reported that severe, excessive, or uncontrolled bleeding during surgery can increase mortality rates to 20%.[@b1-ceor-7-409],[@b3-ceor-7-409] It has also been estimated that uncontrollable bleeding accounts for approximately 40% of trauma-related deaths.[@b29-ceor-7-409]

Despite available data describing the burden of difficult or uncontrollable bleeding, there is still a need to understand how hemostat use impacts the incidence of such bleeding, and the risk of associated complications. Currently, no studies have explicitly assessed the burden of surgical bleeding in relation to hemostat use. Consequently, this retrospective analysis of the Premier database was conducted to estimate the hospital resources and costs that remain associated with uncontrolled surgical bleeding, even when hemostatic agents are used during surgery.

Methods
=======

Study design and data source
----------------------------

A retrospective analysis was conducted using data from the Premier Perspectives Database (PPD). Information contained within the PPD is de-identified making it fully compliant with the Health Insurance Portability and Accountability Act (HIPAA). The PPD includes data on more than 600 participating hospitals and 47 million hospital discharges in the US. Participating hospitals submit data on patient demographic and payer information as captured on the hospital billing record. Before the information is added to the database, all data go through quality assurance and validation checks. Available data include all billed items by the cost-accounting department, including medications; laboratory, diagnostic, and therapeutic services; and primary and secondary diagnoses for each patient. Further, hospital information, such as geographical location, bed size, and teaching hospital status, is also included within the PPD.

Patient population
------------------

All hospital discharges with admission dates in 2012 were used to identify patients who were treated with hemostatic agents during select surgeries. Eight major surgeries were selected that were deemed by surgeons to be commonly associated with major bleeding and included cardiac revascularization, cardiac valve surgery, cholecystectomy, cystectomy, pancreatic, partial hepatic resection, pulmonary, and radical abdominal hysterectomy. Surgeries of interest were identified using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) procedure codes ([Table S1](#SD1-ceor-7-409){ref-type="supplementary-material"}). Specific hemostatic agents used in surgery included mechanical, thrombin, flowable, and fibrin sealant agents ([Table S2](#SD2-ceor-7-409){ref-type="supplementary-material"}). Patients were identified for inclusion if they were admitted to a hospital in 2012, underwent an inpatient surgery of interest as the primary procedure, and received a hemostatic agent on the day of the surgery. Patients were excluded if they were less than 18 years old or had received an additional major surgical procedure on a different body system on the same day as the index procedure. For patients with multiple hospitalizations, only the first was included for analysis.

Major bleeding events
---------------------

Within each of the eight surgery subgroups, patients were further stratified by the presence or absence of a major bleeding (ie, uncontrolled bleeding) event despite hemostat use. Major bleeding events were identified by following the ICD-9-CM diagnosis and procedure codes: hemorrhage or hematoma complicating a procedure (998.11 and 998.12); interventions to control bleeding (34.09, 39.98, 44.44, 44.49, 54.19, 39.41, 34.03, 54.12, 57.93); charges billed for use of hemovac drainage devices; charges billed for use of erythropoietin; blood product transfusions (99.00--99.09); and charges billed for cryoprecipitates, fresh frozen plasma, red blood cells, plasma, platelets, and whole blood. A detailed listing of these major bleeding events is outlined in [Table S3](#SD3-ceor-7-409){ref-type="supplementary-material"}.

Study outcomes
--------------

The main study outcomes included in the study were the all-cause costs incurred during hospitalization, the cost of hemostatic agents, length of stay (LOS) between surgery and discharge, intensive care unit (ICU) stay, operation time, reoperation, and potential surgery-related complications (eg, mortality, infection, transfusions, ventilator use). Total all-cause costs included room and board, surgery, professional fees, supplies, pharmacy services, and laboratory services. Reoperation was defined as procedures on the same body system as the original procedure, performed during the same hospitalization. Additionally, both infections and transfusions were defined according to specific ICD-9-CM codes, which are summarized in [Tables S4](#SD4-ceor-7-409){ref-type="supplementary-material"} and [S5](#SD5-ceor-7-409){ref-type="supplementary-material"}, respectively. Other study measures included were patient demographics, payment source, admitting hospital characteristics, type of hemostatic agents used (eg, mechanical, active, flowable, fibrin sealant), and the all payer refined-diagnosis related groups (APR-DRGs). The APR-DRG simultaneously evaluates the interactions of multiple comorbidities, age, and primary and secondary discharge diagnoses.

Statistical analyses
--------------------

All data transformations and statistical analyses were performed using SAS^®^ version 9.4 (SAS Institute, Cary, NC, USA). Patient demographics and hospital characteristics were evaluated for all surgical subgroups combined. Descriptive statistics (eg, means, patient counts) were stratified by the presence or absence of major (ie, uncontrolled) bleeding events. All statistical analyses on outcome measures were conducted separately for each surgical subgroup. Chi-square or *t*-tests were used to test for statistical significance whenever applicable; all tests were two-sided with a significance level of 0.05. Multivariate analyses were conducted to compare all-cause costs and LOS between patients with and without uncontrolled bleeding. Patient demographics and admitting hospital characteristics thought to have an impact on costs and LOS were included into the multivariate analysis, including age, race, sex, payment source, hospital geographic region, hospital location (rural vs urban), surgical admission type (elective vs emergent), teaching hospital status, and bed size. Analysis of covariance (ANCOVA) was used to adjust for these baseline characteristics.

Results
=======

A total of 50,696 patients were identified within the Premier database that underwent a selected surgery in 2012, of which 25,155 were excluded because no hemostatic agent was used during surgery ([Figure 1](#f1-ceor-7-409){ref-type="fig"}). Of the remaining 25,541 patients, 125 were excluded as they were younger than 18 years, and 368 were further excluded because they required additional surgery on a different body system on the same day. Thus, 25,048 patients were included in the analysis (cardiac revascularization: 12,799; cardiac valve surgery: 8,016; cholecystectomy: 1,576; cystectomy: 423; pancreatic: 464; partial hepatic: 620; pulmonary: 954; radical abdominal hysterectomy: 196).

Patient demographics and admitting hospital characteristics are presented in [Tables 1](#t1-ceor-7-409){ref-type="table"} and [2](#t2-ceor-7-409){ref-type="table"}. There were some notable differences between controlled and uncontrolled bleeding patients. In particular, there was a larger percentage of urgent cases in the uncontrolled versus controlled bleeding group (ie, 52% vs 40%), as well as a higher proportion of extreme APR-DRG disease severity in uncontrolled versus controlled bleeding (ie, 28% vs 8.4%).

Among 25,048 procedures, 14,251 uncontrolled bleeding events were recorded. The prevalence of uncontrolled bleeding events within each surgical subgroup is presented in [Figure 2](#f2-ceor-7-409){ref-type="fig"}. Despite the use of hemostatic agents, uncontrolled bleeding events occurred in 32%--68% of patients, depending on the type of procedure. The most common type of event was use of a blood product, which occurred in 49.0% of all patients. Within the uncontrolled bleeding cohort, 25%--71% of patients required transfusions, with 5.8%--32.8% of patients receiving platelets, and up to 3.2% receiving coagulation factors. By definition, patients in the controlled bleeding cohort did not require transfusions.

Mortality for each surgical subgroup, stratified by the presence of uncontrolled bleeding despite hemostat use, is presented in [Figure 3](#f3-ceor-7-409){ref-type="fig"}. Mortality was statistically significantly higher in the uncontrolled versus controlled bleeding cohort in all surgical subgroups except cystectomy and radical hysterectomy. Mortality rates ranged from 1.2% to 7.3% for uncontrolled bleeding and 0% to 1.2% for controlled bleeding cohorts.

Results pertaining to hospital resource use and costs are presented in [Tables 3](#t3-ceor-7-409){ref-type="table"} and [4](#t4-ceor-7-409){ref-type="table"} for each surgical group, stratified by the presence or absence of uncontrolled bleeding despite hemostat use. All-cause costs were statistically significantly greater in patients with uncontrolled bleeding versus controlled bleeding for all surgery subgroups (uncontrolled bleeding: US\$24,203--\$61,323 vs controlled bleeding: US\$14,420--\$45,593; *P*\<0.001). Similarly, LOS was also statistically significantly greater with uncontrolled bleeding patients for all subgroups (uncontrolled bleeding: 7.1--17 days vs controlled bleeding: 4.1--10 days; *P*\<0.001). After adjusting for baseline differences, results for all-cause costs and LOS were consistent with unadjusted values ([Table 4](#t4-ceor-7-409){ref-type="table"}).

The cost of hemostatic agents was also statistically significantly greater in the uncontrolled bleeding cohort for all surgical groups, except pancreatic surgery and cystectomy (uncontrolled bleeding: US\$287--\$799 vs controlled bleeding: US\$203--\$451) ([Table 3](#t3-ceor-7-409){ref-type="table"}). Furthermore, ICU stay and infection were always statistically significantly greater in the uncontrolled versus controlled bleeding cohorts, across surgery subgroups. Reported infections included urinary tract infections, septicemia, fever, and pneumonia. Reoperation rates were also statistically significantly greater in uncontrolled bleeding patients, with the exception of radical abdominal hysterectomy. Ventilator use was also more common in uncontrolled bleeding in all surgery cohorts except cystectomy. Finally, operating time was typically higher in uncontrolled versus controlled bleeding cohorts by 13.3--37.6 minutes, but differences were only statistically significant for cardiac revascularization, cardiac valve surgery, pulmonary surgery, and radical hysterectomy ([Table 3](#t3-ceor-7-409){ref-type="table"}).

Discussion
==========

Using a sample of over 25,000 patients, we found that a substantial proportion of patients have uncontrolled surgical bleeding despite current hemostat use, with rates ranging from 32% to 68% depending on the procedure. Both infection rate and mortality were statistically significantly higher for uncontrolled versus controlled bleeding cohorts for all surgery types. Resource use, including length of hospital stay, ICU stay, ventilator use, operation time, and reoperation were often higher in patients with uncontrolled bleeding. These results were consistent with adjusted all-cause costs, which were always significantly greater in uncontrolled versus controlled bleeding cohorts.

Several studies have reported on the risk of surgical bleeding; however, reported rates span a wide range, which may be due to varying definitions of bleeding, differences in study design and geographic location, as well as variations in surgical procedures studied.[@b1-ceor-7-409],[@b5-ceor-7-409],[@b15-ceor-7-409],[@b24-ceor-7-409] For example, a recent study by Dyke et al[@b1-ceor-7-409] reported a major (ie, moderate or severe/massive) bleeding rate of 33.8% in cardiac surgery. Classification of major bleeding in this study depended on the amount of total blood loss, transfusion units, need for surgical re-exploration, and whether there was delayed sterna closure. This rate is reportedly lower than the observed rate of 56%--68% in cardiac revascularization or valve surgery in this study. Another study by Stone et al[@b5-ceor-7-409] reported a major bleeding rate in the US cardiac surgery patients of 52.9% where the bleeding definition encompassed decrease in hemoglobin levels, reoperation for bleeding, access site hemorrhage requiring intervention, ≥5 cm hematoma, or transfusion. Other studies reported major or excessive bleeding rates of lower than 10%; however, those studies used a more restrictive definition, which specified the number of transfusion units needed to qualify under the bleeding definition[@b24-ceor-7-409] or the amount of postoperative bleeding drainage in cardiac surgery.[@b15-ceor-7-409] Our study included more liberal definitions of uncontrolled bleeding as well as several additional surgery types relative to these latter studies. Also, our study included eight surgery types deemed by surgeons to be commonly associated with major bleeding. Furthermore, unlike our study which focused solely on surgeries involving hemostat use, it is unclear to what extent hemostats were used in most of these published studies reporting bleeding risk.

These current study findings are aligned with studies that have quantified resource use and costs associated with surgical bleeding. An earlier 2011 US study by Stokes et al[@b23-ceor-7-409] reported that patients with bleeding-related complications (eg, transfusions) across different surgery types had significantly greater hospital costs and longer LOS. Our current study adds additional granularity in the types of resources comprising greater hospital costs in uncontrolled bleeding patients, such as reoperation, infection treatment, and ICU stay. Further, our study uniquely shows that these additional resources and costs are still high despite single or multiple hemostat product use. From the European perspective, Christensen et al[@b15-ceor-7-409] demonstrated that hospital costs and resources including ICU stay, ventilator, and reoperation were significantly higher in patients with excessive postoperative bleeding compared to patients without.

The uptake of hemostats has been rapid over the last several years. A study by Wright et al[@b14-ceor-7-409] showed that hemostat use continues to rise even for surgical procedures that are associated with very low bleeding complication and transfusion risk. Reviews of randomized trials demonstrate that hemostats can improve hemostasis and certain resource outcomes (eg, transfusions); however, benefits may vary by patient population type and hemostat product used.[@b30-ceor-7-409]--[@b34-ceor-7-409] In surgical situations where bleeding is more difficult to control, combined use of multiple hemostats is sometimes undertaken to try to achieve hemostasis.[@b12-ceor-7-409],[@b21-ceor-7-409] In our study, hemostat costs have been observed to be significantly higher in patients with uncontrolled bleeding, which may be partially explained by more combination hemostat use. Despite these additional hemostat costs, uncontrolled bleeding rates and associated resource use remained high, signifying the suboptimal benefit that some currently approved hemostats may have. Limitations with such hemostats, including insufficient adhesion strength, lack of efficacy in a wet field, and inability to withstand forces of brisk hemorrhage, may explain the continued risk of uncontrolled bleeding in many surgery types.[@b9-ceor-7-409],[@b12-ceor-7-409],[@b18-ceor-7-409]--[@b20-ceor-7-409]

To address the prevalent problem of difficult-to-control surgical bleeding, a multifaceted approach is required. Essentially, methods to better assess appropriateness of operation technique and use of the various surgical methods for hemostasis are needed. Optimizing the use of right hemostatic technique (or product) with the right procedure can be an important goal for continuing education. Furthermore, new hemostats becoming available on the market that are targeted to problematic bleeding situations may help to alleviate this burden. The EVARREST^®^ fibrin sealant patch is one novel bioabsorbable combination product composed of human fibrinogen and thrombin along with a flexible composite patch that provides mechanical integrity and supports clot formation.[@b35-ceor-7-409] EVARREST^®^ is supported by several clinical studies across challenging bleeding populations demonstrating rapid onset of action with high hemostasis efficacy.[@b27-ceor-7-409],[@b36-ceor-7-409] A recent economic evaluation also showed that this new fibrin sealant patch was predicted to be cost saving in problematic surgical bleeding for hospital stakeholders due to hospital resources averted, such as transfusions and bleeding retreatment, versus standard of care.[@b37-ceor-7-409] Such results are particularly relevant in light of the findings of the current study showing significantly greater hemostat costs in uncontrolled bleeding cohorts. Several additional new hemostatic agents have also been developed that are currently undergoing clinical trials. Examples of these products include Veriset™ hemostatic patch (Covidien Inc., Mansfield, MA, USA), Fibrocaps™ (ProFibrix, Leiden, the Netherlands), and Hemopatch Sealing Hemostat (Baxter International, Deerfield, IL, USA). These products have numerous ongoing trials for the treatment of surgical bleeding across a wide range of surgery types with demonstrated effectiveness in some trials.[@b38-ceor-7-409]--[@b41-ceor-7-409] No economic evaluations have been published to date with these products.

Limitations
===========

This study is not without limitations. First, it was retrospective; therefore, it was not possible to control for all potential confounding variables as can be done within a randomized controlled trial. Second, limitations of this study include those common to all claims-based studies. Specifically, the data for this study were derived from hospital discharge records designed to be used for billing rather than research. There is some degree of miscoding that is common in these records, and the records were not independently validated. Furthermore, data such as these miss clinical details that ideally would be used to further explain study results. For example, there are no disease-specific measures of severity, no clinical assessments of preoperative risk (eg, hematocrit levels), and no data on surgeon's skill level and techniques used. This information could not be captured and could not be evaluated or controlled for, as this was a retrospective database analysis. However, the potential impact of several patient and hospital characteristics was controlled for in adjusted multivariate analyses for the all-cause hospital costs as well as length of hospital stay, with adjustment having little impact on overall conclusions. Third, data are limited to the index hospitalization, so pre-existing comorbidities are not well captured. Fourth, data were only collected on hemostat class (eg, active, fibrin sealant, mechanical), and therefore it was not possible to conduct analyses on the association between specific hemostat products and bleeding control. Such information would have been useful for assessing the extent to which multiple product use or more expensive products contributed to the significantly higher total hemostat cost per patient in the uncontrolled bleeding cohort.

Conclusion
==========

Despite the use of hemostatic agents, uncontrolled bleeding is common and is associated with significantly higher costs; longer hospitalization; and higher rates of reoperation and mortality in multiple major surgical procedures compared to controlled bleeding. There is an unmet need for newer hemostats that can improve clinical outcomes in surgery and minimize the economic burden to hospitals and payers. Future studies need to assess the clinical and economic impact of newer, highly efficacious hemostats in real-world, difficult-to-control bleeding populations.

Supplementary materials
=======================

###### 

Selected primary surgical procedures

  ICD-9-CM procedure code             Description
  ----------------------------------- -------------------------------------------------------------------
  Cardiac revascularization surgery   
   36.03                              Open chest coronary artery angioplasty
   36.1x                              Bypass anastomosis for heart revascularization
   36.2                               Heart revascularization by arterial implant
   36.32                              Other transmyocardial revascularization
   36.39                              Other heart revascularization
  Cardiac valve surgery               
   35.1x                              Open heart valvuloplasty without replacement
   35.2x                              Replacement of heart valve
   35.3x                              Operations on structures adjacent to heart valves
   35.99                              Other operations on valves of heart
  Cholecystectomy                     
   51.21                              Other partial cholecystectomy (revision of prior cholecystectomy)
   51.22                              Cholecystectomy (open)
  Cystectomy                          
   57.71                              Radical cystectomy
   57.79                              Other total cystectomy
  Pancreatic surgery                  
   52.51                              Proximal pancreatectomy
   52.52                              Distal pancreatectomy
   52.53                              Radical subtotal pancreatectomy
   52.59                              Other partial pancreatectomy
   52.6                               Total pancreatectomy
   52.7                               Radical pancreaticoduodenectomy (Whipple procedure)
  Partial hepatic resection           
   50.22                              Partial hepatectomy (wedge resection of liver)
   50.3                               Lobectomy of liver
  Pulmonary surgery                   
   32.39                              Other and unspecified segmental resection of lung
   32.49                              Other lobectomy of lung
   32.59                              Other and unspecified pneumonectomy
  Radical abdominal hysterectomy      
   68.69                              Other and unspecified radical abdominal hysterectomy

###### 

Hemostatic agents

  Category         Products
  ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mechanical       Gelfoam^®^, Gelfoam Plus^®^, Surgifoam^®^, Avitene™ sheets, Avitene Ultrafoam™ collagen sponges, HELISTAT^®^ & HELITENE^®^, INSTAT^®^ MCH, Surgicel^®^, Surgicel Fibrillar™, Surgicel Nu-Knit^®^, Arista^®^AH, Hemostase MPH^®^, Vitasure™
  Active           Thrombin-JMI^®^, Evithrom^®^, Recothrom^®^
  Flowable         Floseal^®^, Surgiflo^®^
  Fibrin sealant   Evicel^®^, Beriplast^®^, TachoSil^®^, Tisseel™, Artiss, Vitagel™, Vivostat^®^

###### 

Major bleeding events

  ICD-9-CM diagnosis or procedure code   Description
  -------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Diagnosis of bleeding                  
   998.11                                Hemorrhage complicating a procedure
   998.12                                Hematoma complicating a procedure
  Procedures to control bleeding         
   34.09                                 Other incision of pleura, including creation of pleural window for drainage, intercostal stab, open chest drainage
   39.98                                 Control of hemorrhage not otherwise specified
   44.44                                 Transcatheter embolization for gastric or duodenal bleeding
   44.49                                 Other control of hemorrhage of stomach or duodenum -- that with gastronomy
   54.19                                 Other laparotomy: drainage of intraperitoneal abscess or hematoma
   39.41                                 Control of hemorrhage following vascular surgery
   34.03                                 Reopening of recent thoracotomy site
   54.12                                 Reopening of recent laparotomy site for: control of hemorrhage, exploration, incision of hematoma
   57.93                                 Control of (postoperative) hemorrhage of bladder
   Charges billed for                    Hemovac drainage devices
  Erythropoietin                         
   Charges billed for                    Epogen, Procrit, Aranesp, Darbepoetin
  Blood products                         
   99.00                                 Perioperative autologous transfusion of whole blood or blood components
   99.02                                 Transfusion of previously collected autologous blood
   99.03                                 Other transfusion of whole blood
   99.04                                 Transfusion of packed cells
   99.05                                 Transfusion of platelets
   99.07                                 Transfusion of other serum
   99.08                                 Transfusion of blood expander
   99.09                                 Transfusion of other substance
  Charges billed for                     Cryoprecipitates, fresh frozen plasma, red blood cells, plasma, platelets, whole blood

###### 

Infections

  ICD-9-CM diagnosis code         Description
  ------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Postoperative infections        
   998.5x                         Postoperative infection
   996.6x                         Infection and inflammatory reaction due to internal prosthetic device, implant, and graft
  Infection due to medical care   
   999.3x                         Other infection: infection due to central venous catheter; infection following other infusion, injection, transfusion, or vaccination
  Septicemia                      
   038.x                          Septicemia
   785.52                         Septic shock
   995.91                         Sepsis
   995.92                         Severe sepsis
   998.0                          Postoperative shock
  Other bacterial infections      
   040.0                          Gas gangrene
   040.8x                         Other specified bacterial diseases
   041.x                          Bacterial infection in conditions classified elsewhere and of unspecified site
   790.7                          Bacteremia
  Skin infections                 
   682.x                          Other cellulitis and abscess
   686.x                          Other local infections of skin and subcutaneous tissue
  Urinary tract infections        
   112.2                          Candidiasis of other urogenital sites
   590.1                          Acute pyelonephritis
   590.3                          Pyeloureteritis cystica
   590.8x                         Other pyelonephritis or pyonephrosis, not specified as acute or chronic
   590.9                          Infection of kidney, unspecified
   595.0                          Acute cystitis
   595.3                          Trigonitis
   599.0                          Urinary tract infection, site not specified
   996.64                         Infection due to indwelling urinary catheter
  Pneumonia                       
   039.1                          Pulmonary actinomycotic infections
   112.4                          Candidiasis of lung
   117.9                          Other and unspecified mycoses
   136.3                          Pneumocystosis
   466.19                         Acute bronchiolitis due to other infectious organisms
   480.x                          Viral pneumonia
   481                            Pneumococcal pneumonia (*Streptococcus pneumoniae* pneumonia)
   482.x                          Other bacterial pneumonia
   483.x                          Pneumonia due to other specified organism
   484.x                          Pneumonia in infectious diseases classified elsewhere
   485                            Bronchopneumonia, organism unspecified
   486                            Pneumonia, organism unspecified
   487.0                          With pneumonia
   507.x                          Pneumonitis due to solids and liquids
   513.0                          Abscess of lung
   516.8                          Other specified alveolar and parietoalveolar pneumonopathies
   997.3x                         Respiratory complications
  Gynecological infections        
   614.0                          Acute salpingitis and oophoritis
   614.2                          Salpingitis and oophoritis not specified as acute, subacute, or chronic
   614.3                          Acute parametritis and pelvic cellulitis
   614.4                          Chronic or unspecified parametritis and pelvic cellulitis
   614.5                          Acute or unspecified pelvic peritonitis, female
   614.6                          Pelvic peritoneal adhesions, female (postoperative) (postinfection)
   614.8                          Other specified inflammatory disease of female pelvic organs and tissues
   614.9                          Unspecified inflammatory disease of female pelvic organs and tissues
   615.0                          Acute inflammatory diseases of uterus, except cervix
   615.9                          Unspecified inflammatory disease of uterus
   670.0x                         Major puerperal infection
   672.0x                         Pyrexia of unknown origin during the puerperium
  Septic embolism                 
   673.3x                         Obstetrical pyemic and septic embolism
  Fever                           
   780.6x                         Fever and other physiologic disturbances of temperature regulation

###### 

Transfusion coding descriptions

  ICD-9-CM procedure or standard charge code   Description
  -------------------------------------------- -------------------------------------------------------------------------
  Transfusion of platelets                     
   99.05                                       Transfusion of platelets
  Transfusion of coagulation factors           
   99.06                                       Transfusion of coagulation factors
  Other transfusion                            
   99.00                                       Perioperative autologous transfusion of whole blood or blood components
   99.01                                       Autologous whole blood transfusion
   99.02                                       Transfusion of previously collected autologous blood
   99.03                                       Other transfusion of whole blood
   99.04                                       Transfusion of packed cells
   99.07                                       Transfusion of other serum
   99.08                                       Transfusion of blood expander
   99.09                                       Transfusion of other substance
   V58.2                                       Blood transfusion, no diagnosis
   380381000010000                             Red Cells Packed 1 Unit
   380381000010007                             Red Cells Packed 7 Units
   380381000010008                             Red Cells Packed 8 Units
   380381000010009                             Red Cells Packed 9 Units
   380381000010010                             Red Cells Packed 10 Units
   380381000020000                             Red Cells Packed 2 Units
   380381000030000                             Red Cells Packed 3 Units
   380381000040000                             Red Cells Packed 4 Units
   380381000050000                             Red Cells Packed 5 Units
   380381000060000                             Red Cells Packed 6 Units
   380381000210000                             Red Cells Autologous 1 Unit
   380381000210005                             Red Cells Autologous 5 Units
   380381000210006                             Red Cells Autologous 6 Units
   380381000210007                             Red Cells Autologous 7 Units
   380381000210008                             Red Cells Autologous 8 Units
   380381000210009                             Red Cells Autologous 9 Units
   380381000210010                             Red Cells Autologous 10 Units
   380381000220000                             Red Cells Autologous 2 Units
   380381000230000                             Red Cells Autologous 3 Units
   380381000240000                             Red Cells Autologous 4 Units
   380381000310000                             Red Cells Leukocyte Poor 1 Unit
   380381000310005                             Red Cells Leukocyte Poor 5 Units
   380381000310006                             Red Cells Leukocyte Poor 6 Units
   380381000310007                             Red Cells Leukocyte Poor 7 Units
   380381000310008                             Red Cells Leukocyte Poor 8 Units
   380381000310009                             Red Cells Leukocyte Poor 9 Units
   380381000310010                             Red Cells Leukocyte Poor 10 Units
   380381000320000                             Red Cells Leukocyte Poor 2 Units
   380381000330000                             Red Cells Leukocyte Poor 3 Units
   380381000340000                             Red Cells Leukocyte Poor 4 Units
   380381000410000                             Red Cells Washed 1 Unit
   380381000410003                             Red Cells Washed 3 Units
   380381000410004                             Red Cells Washed 4 Units
   380381000410005                             Red Cells Washed 5 Units
   380381000410006                             Red Cells Washed 6 Units
   380381000410007                             Red Cells Washed 7 Units
   380381000410008                             Red Cells Washed 8 Units
   380381000410009                             Red Cells Washed 9 Units
   380381000410010                             Red Cells Washed 10 Units
   380381000420000                             Red Cells Washed 2 Units
   380381000510000                             Red Cells Deglycerolized 1 Unit
   380381000510003                             Red Cells Deglycerolized 3 Units
   380381000510004                             Red Cells Deglycerolized 4 Units
   380381000510005                             Red Cells Deglycerolized 5 Units
   380381000510006                             Red Cells Deglycerolized 6 Units
   380381000510007                             Red Cells Deglycerolized 7 Units
   380381000510008                             Red Cells Deglycerolized 8 Units
   380381000510009                             Red Cells Deglycerolized 9 Units
   380381000510010                             Red Cells Deglycerolized 10 Units
   380381000520000                             Red Cells Deglycerolized 2 Units
   380381000610000                             Red Cells Directed 1 Unit
   380381000610002                             Red Cells Directed 2 Units
   380381000610003                             Red Cells Directed 3 Units
   380381000610004                             Red Cells Directed 4 Units
   380381000610005                             Red Cells Directed 5 Units
   380381000610006                             Red Cells Directed 6 Units
   380381000610007                             Red Cells Directed 7 Units
   380381000610008                             Red Cells Directed 8 Units
   380381000610009                             Red Cells Directed 9 Units
   380381000610010                             Red Cells Directed 10 Units
   380382000010000                             Whole Blood 1 Unit
   380382000010002                             Whole Blood 2 Units
   380382000010003                             Whole Blood 3 Units
   380382000010004                             Whole Blood 4 Units
   380382000010005                             Whole Blood 5 Units
   380382000010006                             Whole Blood 6 Units
   380382000010007                             Whole Blood 7 Units
   380382000010008                             Whole Blood 8 Units
   380382000010009                             Whole Blood 9 Units
   380382000010010                             Whole Blood 10 Units
   380382000210000                             Whole Blood Autologous 1 Unit
   380382000210005                             Whole Blood Autologous 5 Units
   380382000210006                             Whole Blood Autologous 6 Units
   380382000210007                             Whole Blood Autologous 7 Units
   380382000210008                             Whole Blood Autologous 8 Units
   380382000210009                             Whole Blood Autologous 9 Units
   380382000210010                             Whole Blood Autologous 10 Units
   380382000220000                             Whole Blood Autologous 2 Units
   380382000230000                             Whole Blood Autologous 3 Units
   380382000240000                             Whole Blood Autologous 4 Units
   380382000310000                             Whole Blood Irradiated 1 Unit
   380382000310002                             Whole Blood Irradiated 2 Units
   380382000310003                             Whole Blood Irradiated 3 Units
   380382000310004                             Whole Blood Irradiated 4 Units
   380382000310005                             Whole Blood Irradiated 5 Units
   380382000310006                             Whole Blood Irradiated 6 Units
   380382000310007                             Whole Blood Irradiated 7 Units
   380382000310008                             Whole Blood Irradiated 8 Units
   380382000310009                             Whole Blood Irradiated 9 Units
   380382000310010                             Whole Blood Irradiated 10 Units
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![Percentage of patients with a major bleeding event despite hemostat use, stratified by surgery group.\
**Notes:** Major bleeding (ie, uncontrolled bleeding) events were defined as: hemorrhage or hematoma complicating a procedure; interventions to control bleeding; charges billed for use of hemovac drainage devices; charges billed for use of erythropoietin; blood product transfusions; and charges billed for cryoprecipitates, fresh frozen plasma, red blood cells, plasma, platelets, and whole blood.](ceor-7-409Fig2){#f2-ceor-7-409}

![Patient mortality, stratified by surgery type and presence or absence of uncontrolled bleeding despite hemostat use.\
**Note:** \*Statistically significant (*P*\<0.001).](ceor-7-409Fig3){#f3-ceor-7-409}

###### 

Baseline patient demographics and admitting hospital characteristics

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1.1                                                               Bleeding not controlled despite hemostat use\   Bleeding controlled with hemostat\   *P*-value
                                                                    (N=14,251)                                      (N=10,797)                           
  ----------------------------------------------------------------- ----------------------------------------------- ------------------------------------ -----------
  Age, mean (SD)                                                    67 (11.9)                                       63.9 (12.0)                          \<0.001

  Female, N (%)                                                     5,359 (37.6)                                    3,143 (29.1)                         \<0.001

  Race, N (%)                                                                                                                                            \<0.001

   White                                                            10,541 (74.0)                                   7,983 (73.9)                         

   Black                                                            1,085 (7.6)                                     702 (6.5)                            

   Other                                                            2,625 (18.4)                                    2,112 (19.6)                         

  Payment source, N (%)                                                                                                                                  \<0.001

   Managed care/commercial                                          3,373 (23.7)                                    3,642 (33.7)                         

   Medicare                                                         8,817 (61.9)                                    5,517 (51.1)                         

   Other                                                            2,061 (14.5)                                    1,638 (15.2)                         

  Admission type, N (%)                                                                                                                                  \<0.001

   Elective                                                         6,840 (48.0)                                    6,469 (59.9)                         

   Urgent/emergent                                                  7,411 (52.0)                                    4,328 (40.1)                         

  Type of hemostatic agent, N (%)                                                                                                                        \<0.001

   Active                                                           1,774 (12.4)                                    1,604 (14.9)                         

   Fibrin sealant                                                   2,287 (16.0)                                    1,401 (13.0)                         

   Mechanical                                                       5,295 (37.2)                                    5,057 (46.8)                         

   Multiple categories[\*](#tfn1-ceor-7-409){ref-type="table-fn"}   4,895 (34.3)                                    2,735 (25.3)                         

   APR-DRG disease severity, N (%)                                                                                                                       \<0.001

   Minor                                                            593 (4.2)                                       1,196 (11.1)                         

   Moderate                                                         3,582 (25.1)                                    4,812 (44.6)                         

   Major                                                            6,040 (42.4)                                    3,884 (36.0)                         

   Extreme                                                          4,036 (28.3)                                    905 (8.4)                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

More than one hemostat used per patient.

**Abbreviations:** N, number of patients; SD, standard deviation; APR-DRG, all payer refined-diagnosis related groups.

###### 

Hospital characteristics

  -------------------------------------------------------------------------------------------------------------------------------
  1.2                           Bleeding not controlled despite hemostat use\   Bleeding controlled with haemostat\   *P*-value
                                (N=14,251)                                      (N=10,797)                            
  ----------------------------- ----------------------------------------------- ------------------------------------- -----------
  Hospital region (US), N (%)                                                                                         \<0.001

   Northeast                    3,057 (21.5)                                    1,848 (17.1)                          

   Midwest                      1,829 (12.8)                                    2,382 (22.1)                          

   West                         2,177 (15.3)                                    2,210 (20.5)                          

   South                        7,188 (50.4)                                    4,357 (40.4)                          

  Teaching hospital, N (%)                                                                                            \<0.001

   Yes                          8,178 (57.4)                                    5,488 (50.8)                          

   No                           6,073 (42.6)                                    5,309 (49.2)                          

  Location of hospital, N (%)                                                                                         \<0.001

   Rural                        1,176 (8.3)                                     1,206 (11.2)                          

   Urban                        13,075 (91.7)                                   9,591 (88.8)                          

  Bed size, N (%)                                                                                                     \<0.001

   \<750                        10,903 (76.5)                                   9,428 (87.3)                          

   750+                         3,348 (23.5)                                    1,369 (12.7)                          
  -------------------------------------------------------------------------------------------------------------------------------

**Abbreviation:** N, number of patients.

###### 

Unadjusted mean (SD) costs and resource use, stratified by surgical procedure and presence or absence of uncontrolled bleeding despite hemostat use

  Surgery type                     All-cause cost, US\$ (SD)   Cost of hemostatic agent, US\$ (SD)   LOS, days (SD)   ICU stay, days (SD)   Operation time, minutes (SD)   Reoperation, N (%)   Infection, N (%)   Ventilator use, N (%)
  -------------------------------- --------------------------- ------------------------------------- ---------------- --------------------- ------------------------------ -------------------- ------------------ -----------------------
  Cardiac revascularization                                                                                                                                                                                        
  Uncontrolled                     44,327 (30,565)             406 (531)                             7.8 (6.4)        5.7 (6.4)             332.3 (129.0)                  989 (13.9)           1,818 (25.5)       6,841 (95.9)
  Controlled                       35,125 (17,601)             254 (329)                             5.7 (3.4)        3.6 (3.8)             312.5 (143.5)                  372 (6.6)            641 (11.3)         5,177 (91.4)
  *P*-value                        \<0.001                     \<0.001                               \<0.001          \<0.001               ,.0001                         \<0.001              \<0.001            \<0.001
  Cardiac valve surgery                                                                                                                                                                                            
   Uncontrolled                    61,323 (44,151)             508 (692)                             10 (8.2)         6.8 (8.8)             376.1 (168.1)                  1,464 (27.0)         1,613 (29.8)       5,219 (96.3)
   Controlled                      45,593 (25,559)             311 (395)                             6.8 (4.5)        4.0 (4.6)             342.5 (179.9)                  365 (14.1)           350 (13.5)         2,426 (93.4)
   *P*-value                       \<0.001                     \<0.001                               \<0.001          \<0.001               \<0.001                        \<0.001              \<0.001            \<0.001
  Cholecystectomy                                                                                                                                                                                                  
   Uncontrolled                    29,582 (27,167)             287 (387)                             8.7 (8.3)        5.6 (6.9)             196.0 (431.8)                  104 (17.1)           260 (42.7)         181 (29.7)
   Controlled                      17,180 (13,448)             203 (275)                             5.0 (3.5)        3.1 (3.3)             173.7 (129.6)                  71 (7.3)             207 (21.4)         79 (8.2)
   *P*-value                       \<0.001                     \<0.001                               \<0.001          \<0.001               0.222                          \<0.001              \<0.001            \<0.001
  Cystectomy                                                                                                                                                                                                       
   Uncontrolled                    40,238 (62,047)             314 (372)                             12 (12.6)        4.4 (5.1)             389.7 (150.2)                  36 (14.3)            70 (27.8)          47 (18.7)
   Controlled                      29,717 (18,431)             352 (533)                             9.0 (4.9)        3.0 (2.9)             484.3 (1320.8)                 11 (6.4)             26 (15.2)          20 (11.7)
   *P*-value                       0.012                       0.424                                 \<0.001          0.010                 0.358                          0.012                0.002              0.055
  Pancreatic surgery                                                                                                                                                                                               
   Uncontrolled                    58,891 (49,789)             457 (618)                             17 (13.2)        7.0 (9.1)             450.5 (155.0)                  63 (27.2)            95 (40.9)          96 (41.4)
   Controlled                      37,001 (28,276)             368 (377)                             10 (8.4)         3.5 (6.9)             437.2 (168.6)                  16 (6.9)             57 (24.6)          31 (13.4)
   *P*-value                       \<0.001                     0.063                                 \<0.001          \<0.001               0.378                          \<0.001              \<0.001            \<0.001
  Partial hepatic resection                                                                                                                                                                                        
   Uncontrolled                    42,819 (54,515)             674 (899)                             9.9 (10.4)       5.9 (8.5)             319.2 (140.4)                  25 (10.7)            59 (25.3)          65 (27.9)
   Controlled                      21,035 (10,874)             451 (411)                             5.5 (2.7)        2.1 (1.9)             294.9 (233.1)                  18 (4.7)             46 (11.9)          24 (6.2)
   *P*-value                       \<0.001                     \<0.001                               \<0.001          \<0.001               0.107                          0.004                \<0.001            \<0.001
  Pulmonary surgery                                                                                                                                                                                                
   Uncontrolled                    40,211 (33,239)             799 (1,053)                           11 (9.6)         8.5 (11.6)            270.8 (118.2)                  83 (27.5)            116 (38.4)         120 (39.7)
   Controlled                      24,361 (14,893)             347 (592)                             7.1 (4.3)        3.6 (3.7)             249.3 (94.7)                   57 (8.7)             106 (16.3)         122 (18.7)
   *P*-value                       \<0.001                     \<0.001                               \<0.001          \<0.001               0.006                          \<0.001              \<0.001            \<0.001
  Radical abdominal hysterectomy                                                                                                                                                                                   
   Uncontrolled                    24,203 (17,854)             592 (625)                             7.1 (5.8)        5.2 (6.4)             280.4 (116.9)                  4 (5.8)              26 (37.7)          10 (14.5)
   Controlled                      14,420 (7,444)              361 (515)                             4.1 (2.5)        2.2 (2.1)             242.8 (100.2)                  3 (2.4)              24 (18.9)          4 (3.1)
   *P*-value                       \<0.001                     0.006                                 \<0.001          \<0.001               \<0.001                        0.245                0.004              0.007

**Abbreviations:** Controlled, controlled bleeding despite hemostat use; uncontrolled, uncontrolled bleeding despite hemostat use; ICU, intensive care unit; LOS, length of stay; N, number of patients; SD, standard deviation.

###### 

Mean adjusted all-cause costs (95% CI) and mean adjusted hospital LOS (95% CI) for controlled versus uncontrolled bleeding in patients treated with hemostatic agents, stratified by surgical procedure

  Surgical category                Adjusted all-cause cost, US\$ (95% CI)   Adjusted length of stay, days (95%CI)                                                    
  -------------------------------- ---------------------------------------- --------------------------------------- --------- ------------------- ------------------ ---------
  Cardiac revascularization        44,198 (43,610--44,785)                  35,288 (34,624--35,951)                 \<0.001   7.7 (7.5--7.8)      5.9 (5.8--6.1)     \<0.001
  Cardiac valve Surgery            60,531 (59,510--61,552)                  47,245 (45,746--48,745)                 \<0.001   9.7 (9.5--9.9)      7.2 (7.0--7.5)     \<0.001
  Cholecystectomy                  29,101 (27,532--30,670)                  17,483 (16,248 --18,718)                \<0.001   8.4 (7.9--8.9)      5.2 (4.8--5.5)     \<0.001
  Cystectomy                       41,708 (35,541--47,876)                  27,551 (19,976--35,126)                 0.006     12.5 (11.2--13.7)   8.8 (7.2--10.3)    \<0.001
  Pancreatic surgery               58,853 (53,503--64,203)                  37,039 (31,689--42,389)                 \<0.001   16.2 (14.7--17.7)   10.8 (9.3--12.3)   \<0.001
  Partial hepatic resection        43,649 (39,188--48,111)                  20,535 (17,106 --23,964)                \<0.001   9.8 (8.9--10.7)     5.6 (4.9--6.2)     \<0.001
  Pulmonary surgery                40,416 (37,886--42,946)                  24,266 (22,564--25,968)                 \<0.001   11.3 (10.5--12.0)   7.1 (6.6--7.6)     \<0.001
  Radical abdominal hysterectomy   23,266 (20,458--26,075)                  14,929 (12,891--16,967)                 \<0.001   6.8 (5.8--7.7)      4.3 (3.6--5.0)     \<0.001

**Note:** Values presented as mean (95% CI).

**Abbreviations:** CI, confidence interval; LOS, length of stay; HA, hemostatic agent.
